These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16675575)

  • 41. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
    Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
    J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
    Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
    Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells.
    Tsui KH; Feng TH; Lin CM; Chang PL; Juang HH
    J Androl; 2008; 29(6):661-8. PubMed ID: 18676361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
    Pang B; Zhang H; Wang J; Chen WZ; Li SH; Shi QG; Liang RX; Xie BX; Wu RQ; Qian XL; Yu L; Li QM; Huang CF; Zhou JG
    Prostate; 2009 Aug; 69(11):1176-87. PubMed ID: 19415690
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.
    Sterbis JR; Gao C; Furusato B; Chen Y; Shaheduzzaman S; Ravindranath L; Osborn DJ; Rosner IL; Dobi A; McLeod DG; Sesterhenn IA; Srivastava S; Cullen J; Petrovics G
    Clin Cancer Res; 2008 Feb; 14(3):758-63. PubMed ID: 18245536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
    He D; Falany CN
    Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo.
    Karsenty G; Rocha J; Chevalier S; Scarlata E; Andrieu C; Zouanat FZ; Rocchi P; Giusiano S; Elzayat EA; Corcos J
    Prostate; 2009 Aug; 69(11):1143-50. PubMed ID: 19399787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rap2 regulates androgen sensitivity in human prostate cancer cells.
    Bigler D; Gioeli D; Conaway MR; Weber MJ; Theodorescu D
    Prostate; 2007 Oct; 67(14):1590-9. PubMed ID: 17918750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overexpression of JKTBP1 induces androgen-independent LNCaP cell proliferation through activation of epidermal growth factor-receptor (EGF-R).
    Wu YY; Li H; Lv XY; Wei Q; Li X; Liu XY; Zhou Q; Wei YQ
    Cell Biochem Funct; 2008 Jun; 26(4):467-77. PubMed ID: 18381662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.
    Gross M; Top I; Laux I; Katz J; Curran J; Tindell C; Agus D
    Clin Cancer Res; 2007 Apr; 13(7):1979-86. PubMed ID: 17404077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hinokitiol, a metal chelator derived from natural plants, suppresses cell growth and disrupts androgen receptor signaling in prostate carcinoma cell lines.
    Liu S; Yamauchi H
    Biochem Biophys Res Commun; 2006 Dec; 351(1):26-32. PubMed ID: 17055455
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The influence of statin medications on prostate-specific antigen levels.
    Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
    Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of prostate-specific antigen expression by the junctional adhesion molecule A.
    Wang Q; Zheng JY; Kreth J; Yan X; Kamata M; Campbell RA; Xie Y; Chiu R; Berenson JR; Shi W; Chen IS; Pang S
    Urology; 2009 May; 73(5):1119-25. PubMed ID: 18602143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.